Topical ropivacaine for analgesia of aplasia cutis congenita in newborns with hereditary epidermolysis bullosa

Table 1 Clinical data of patients enrolled in this study

Patient	Age	Birth weight	Term	EB type	ACC	Background therapy	Premedication before care	Ropivacaine 2 mg/ml quantity per day/ duration	Non pharma-cological analgesic	Apnea during care
1	5.5 y	3000 g	41w	AR dystrophic EB, severe	2 feet	Paracetamol, morphine, ketamine, amitriptyline	Morphine, ketamine, NO	0.5 to 1 mg/4 y	Sucrose	–
2	4.5 y	2530 g	38w	Junctional intermediate	2 feet, 2 wrists	Paracetamol, morphine	Morphine, ketamine	0.5 mg/30 d	Sucrose	Yes
3	4.5 y	3400 g	38w	AD EB, simplex severe	left ankle	Paracetamol, amitriptyline	Morphine	0.05 mg/31 d	Sucrose	–
4	20 m	3380 g	38w	AD EB simplex, severe	2 legs	Paracetamol, morphine, ketamine, then sedated condition then paracetamol, morphine, midazolam, amitriptyline, chlorpromazine	Morphine, ketamine, NO then morphine, chlorpromazine	0.2 mg/30 d	Sucrose	Yes
5	13 m	3150 g	40w	AD EB simplex, severe	2 ankles	Paracetamol	Morphine, ketamine, amitriptyline	0.2 mg/45 d	Sucrose	–
6	9 m	3170 g	37w	Junctional intermediate	2 knees, feet, forearms and hands	Paracetamol, morphine	Morphine, ketamine	0.8 mg/14 d	Sucrose	–
7	8 m	2680 g	37w	AD EB simplex, severe	2 legs	Paracetamol, morphine, ketamine,	Morphine, ketamine, midazolam	0.2 mg/10 d	Sucrose	–
8	6 m	3000 g	39w	AR dystrophic EB, severe	2 feet	Paracetamol	Morphine	0.4 mg/10 d	Sucrose	–

EB Epidermolysis bullosa, ACC aplasia cutis congenita, AD autosomal dominant, AR autosomal recessive, NO nitrous oxide

ISSN: 1750-1172